title: Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.
abstract: BACKGROUND
  Malignant pleural effusion is a common sequelae in patients with certain malignancies. It represents a terminal condition with short median survival (in terms of months) and the goal is palliation. Aim of our study is to analyze morbidity, mortality and life expectancy following videothoracoscopic talc poudrage.
  
  
  METHODS
  From September 2004 to October 2009, 400 patients underwent video-assisted thoracic surgery (VATS) for malignant pleural effusion. The conditions of patients were assessed and graded before and after treatment concerning morbidity, mortality, success rate of pleurodesis and median survival.
  
  
  RESULTS
  The median duration of follow up was 40 months (range 4-61 months). All patients demonstrated notable improvement in dyspnea. Intraoperative mortality was zero. The procedure was well tolerated and no significant adverse effects were observed. In hospital mortality was 2% and the pleurodesis success rate was 85%. A poor Karnofsky Performance Status and delay between diagnosis of pleural effusion and pleurodesis were statistically significant factors for in-hospital mortality. The best survival was seen in breast cancer, followed by ovarian cancer, lymphoma and pleural mesothelioma.
  
  
  CONCLUSIONS
  Video-assisted thoracoscopic talc poudrage is an effective and safe procedure that yields a high rate of successful pleurodesis and achieves long-term control with marked dyspnea decrease.
authors.affiliation: Thoracic Surgery Department, Theagenio Cancer Hospital, A, Simeonidi 2, Thessaloniki, 54007, Greece. nibarbet@yahoo.gr
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Barbetakis
authors.forename: Christos
authors.initials: C
authors.lastname: Asteriou
authors.forename: Fani
authors.initials: F
authors.lastname: Papadopoulou
authors.forename: Georgios
authors.initials: G
authors.lastname: Samanidis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Paliouras
authors.forename: Athanassios
authors.initials: A
authors.lastname: Kleontas
authors.forename: Konstantina
authors.initials: K
authors.lastname: Lyriti
authors.forename: Ioannis
authors.initials: I
authors.lastname: Katsikas
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Tsilikas
mesh_terms: D006801:Humans; D010166:Palliative Care; D016066:Pleural Effusion, Malignant / Q000401:mortality / Q000628:therapy*; D018700:Pleurodesis / Q000009:adverse effects; D012008:Recurrence; D013627:Talc / Q000008:administration & dosage* / Q000009:adverse effects; D013906:Thoracoscopy; D014741:Video Recording
chemical_list: D013627:Talc
references.citation: Am J Respir Crit Care Med. 2000 Nov;162(5):1987-2001
references.pmid: 11069845
references.citation: Curr Opin Pulm Med. 2009 Jul;15(4):380-7
references.pmid: 19436206
references.citation: West J Surg Obstet Gynecol. 1958 Jan-Feb;66(1):26-8
references.pmid: 13507360
references.citation: Ann Thorac Surg. 2002 Jul;74(1):213-7
references.pmid: 12118761
references.citation: Eur J Cardiothorac Surg. 2002 Feb;21(2):302-5; discussion 305-6
references.pmid: 11825740
references.citation: Ann Thorac Surg. 2001 Jun;71(6):1809-12
references.pmid: 11426752
references.citation: Acta Chir Hung. 1999;38(2):155-7
references.pmid: 10596319
references.citation: Chest. 1989 Feb;95(2):320-4
references.pmid: 2914482
references.citation: Ann Intern Med. 1988 Mar;108(3):345-9
references.pmid: 3341671
references.citation: Chest. 2005 Sep;128(3):1798-804
references.pmid: 16162789
references.citation: Chest. 2001 Jul;120(1):19-25
references.pmid: 11451810
references.citation: Chest. 2001 Mar;119(3):801-6
references.pmid: 11243960
references.citation: World J Surg Oncol. 2004 May 20;2:16
references.pmid: 15153245
references.citation: Ann Thorac Surg. 1996 Dec;62(6):1655-8
references.pmid: 8957368
references.citation: Chest. 1993 Apr;103(4 Suppl):385S-389S
references.pmid: 7681744